Neuroone Medical Technologies (NMTC) Non-Current Deferred Tax Liability (2021 - 2022)
Neuroone Medical Technologies (NMTC) reported Non-Current Deferred Tax Liability of $140538.0 for Q3 2022, up 118.94% year-over-year from $64189.0 in Q3 2021, and up 118.94% sequentially from $64189.0 in Q3 2021.
Neuroone Medical Technologies (NMTC) Non-Current Deferred Tax Liability (2021 - 2022) Analysis & Trends
Neuroone Medical Technologies has disclosed Non-Current Deferred Tax Liability across 2 years of filings, most recently posting $140538.0 for Q3 2022.
- Quarterly Non-Current Deferred Tax Liability rose 118.94% year-over-year to $140538.0 in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $140538.0 (up 118.94% YoY) and the FY2022 annual result came in at $140538.0, up 118.94% from the prior year.
- Non-Current Deferred Tax Liability grew to $140538.0 in Q3 2022, from $64189.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $140538.0 in Q3 2022 and bottomed at $64189.0 in Q3 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn |
| 10 | Neuroone Medical Technologies | 26.73 Mn | 23.93 Mn | 990,264.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 140,538.00 |
| Sep 30, 2022 | 140,538.00 |
| Sep 30, 2021 | 64,189.00 |
| Sep 30, 2021 | 64,189.00 |